{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(1)"],"submitter":["Alpuche-Lazcano SP"],"pubmed_abstract":["<h4>Background</h4>As the COVID-19 pandemic continues to evolve, novel vaccines need to be developed that are readily manufacturable and provide clinical efficacy against emerging SARS-CoV-2 variants. Virus-like particles (VLPs) presenting the spike antigen at their surface offer remarkable benefits over other vaccine antigen formats; however, current SARS-CoV-2 VLP vaccines candidates in clinical development suffer from challenges including low volumetric productivity, poor spike antigen density, expression platform-driven divergent protein glycosylation and complex upstream/downstream processing requirements. Despite their extensive use for therapeutic protein manufacturing and proven ability to produce enveloped VLPs, Chinese Hamster Ovary (CHO) cells are rarely used for the commercial "],"journal":["Communications medicine"],"pagination":["116"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10447459"],"repository":["biostudies-literature"],"pubmed_title":["Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells."],"pmcid":["PMC10447459"],"pubmed_authors":["Star A","Cass B","Durocher Y","Maltais JS","Dudani R","Cui K","Cho JY","Blouin J","Stuible M","Alpuche-Lazcano SP","Tran A","Zoubchenok D","Duque D","McCluskie MJ","Hrapovic S","Haqqani A","Renner TM","Kelly J","Robotham A","Akache B","Wang X"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells.","description":"<h4>Background</h4>As the COVID-19 pandemic continues to evolve, novel vaccines need to be developed that are readily manufacturable and provide clinical efficacy against emerging SARS-CoV-2 variants. Virus-like particles (VLPs) presenting the spike antigen at their surface offer remarkable benefits over other vaccine antigen formats; however, current SARS-CoV-2 VLP vaccines candidates in clinical development suffer from challenges including low volumetric productivity, poor spike antigen density, expression platform-driven divergent protein glycosylation and complex upstream/downstream processing requirements. Despite their extensive use for therapeutic protein manufacturing and proven ability to produce enveloped VLPs, Chinese Hamster Ovary (CHO) cells are rarely used for the commercial ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-04-29T02:25:46.383Z","creation":"2025-02-19T04:01:44.253Z"},"accession":"S-EPMC10447459","cross_references":{"pubmed":["37612423"],"doi":["10.1038/s43856-023-00340-7"]}}